top of page
Browse by category
Search


First subject receives DR10624 for the treatment of obesity and hypertriglyceridemia
Zhejiang Doer Biologics, a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and...


MEDICAL IP gains FDA approval for DeepCatch AI software for whole-body composition CT quantification
MEDICAL IP, an AI-based digital twin company, has revealed its CT-based automatic body composition analysis AI software, DeepCatch, has...

GI Dynamics rebrands as Morphic Medical and reintroduces RESET, formerly the EndoBarrier
GI Dynamics, the creator of the EndoBarrier device designed to target the underlying cause of type 2 diabetes, has announced it has...


Phenomix Sciences launches MyPhenome Hungry Brain phenotype swab test
Phenomix Sciences has launched its second of its gut-brain axis phenotyping test, MyPhenome Hungry Brain, new buccal swab test that...


Positive results for mizagliflozin in post-bariatric hypoglyceamia patients
Vogenx has announced positive results from its VGX 001-011 study, a phase 2 multi-centre, randomised, sequential crossover, single...

Eiger BioPharmaceuticals to focus Avexitide for hyperinsulinemic hypoglycaemia indications
Eiger BioPharmaceuticals has revealed it will focus its development efforts on advancing avexitide in hyperinsulinemic hypoglycaemia...


NICE needs more evidence before recommending tirzepatide for T2DM treatment
The UK’s National Institute for Health and Care Excellence (NICE) has not recommended tirzepatide (Mounjaro, developed by Eli Lilly) in...


ReShape submits PMA to FDA for next-generation lap-band 2.0
ReShape Lifesciences has submitted a Premarket Approval (PMA) supplement application to the FDA for the company’s next generation,...

Allurion and Medtronic to expand access to AI-powered weight loss programme
Allurion has entered a pilot collaboration agreement with Medtronic, to expand access to Allurion’s AI-powered weight loss programme...


Novo Nordisk to protect US patients from unlawful sales of non-FDA approved ‘semaglutide medicines’
Novo Nordisk is taking multiple actions to protect US patients from the unlawful marketing and sales of non-FDA approved counterfeit and...
Browse by tag





bottom of page